| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Stifel analyst Thomas Stephan reinstates Globus Medical (NYSE:GMED) with a Hold and announces $64 price target.
 
																	 
																	Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a ...
 
																	Wells Fargo analyst Vik Chopra maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $76 t...
 
																	Globus Medical (NYSE:GMED) affirms FY2025 Adj EPS guidance from $3.00-$3.30 to $3.00-$3.30 vs $3.16 analyst estimate. Affirms F...
 
																	Globus Medical (NYSE:GMED) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.76 by...
 
																	
 
																	
 
																	Canaccord Genuity analyst William Plovanic maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from ...